Scharp Technologies was founded by Dr. David Scharp, MD in 2010. Dr. Scharp began his career at the Washington University School of Medicine, St. Louis, MO, as an academic surgeon and researcher in islet transplantation for nearly 30 years, producing over 200 publications with continuous NIH (National Institutes of Health) and JDRF (Juvenile Diabetes Research Foundation) funding and 13 patents to date. Dr. Scharp’s experience with mesenchymal stem cells originated and coexisted with his work with human islets.
In 2006, Dr. Scharp founded Prodo Laboratories, Inc. and the Scharp-Lacy Research Institute, a not-for-profit California public benefit company that focuses on performing diabetes research. Scharp Technologies was formed to separate the practical applications for its products from those related to diabetes research. Scharp Technologies is dedicated to providing advanced solutions to improve the lives of people suffering from skin-related conditions.